Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women (FLAG)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01266213 |
|
Recruitment Status : Unknown
Verified April 2017 by Young-Hyuck Im, Samsung Medical Center.
Recruitment status was: Active, not recruiting
First Posted : December 24, 2010
Last Update Posted : May 1, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Fulvestrant is an ER antagonist with no agonist effects, which binds, blocks and degrades the ER. Fulvestrant is comparable to third-generation aromatase inhibitors in terms of efficacy and tolerability for patients who have progressed on prior tamoxifen therapy and past studies have found all three-third-generation AIs to be at least as good as tamoxifen in first-line metastatic therapy in postmenopausal women. Fulvestrant has been studied little in premenopausal women despite of its attractive mechanism of actions. The clinical effectiveness of fulvestrant as a treatment for advanced breast cancer has previously been demonstrated at the standard dose (AD; 250 mg/mo) in several phase III clinical trials in postmenopausal women. However, there is evidence to suggest that doses of fulvestrant higher than 250 mg may have greater pharmacodynamic activity against the ER pathway. Moreover, dose-dependent clinical activity has been observed for fulvestrant. The activity of a fulvestrant high-dose (HD; 500 mg/mo) regimen has been investigated in two recent studies. A pilot Japanese study showed fulvestrant HD to have clinical activity in the treatment of advanced or recurrent breast cancer, to be well tolerated, and to result in plasma levels approximately double those seen with fulvestrant low-dose. Subsequently, a neoadjuvant study comparing fulvestrant low-dose and high-dose reported that significantly greater Ki67 and ER downregulation was achieved with the high-dose compared with the low-dose regimen and that both doses were well tolerated. A recent randomized trial also showed superior outcome of high-dose fulvestrant than AI.
Based on this rationale, we introduced high-dose fulvestrant with LHRH agonist as a randomized trial comparing with AI plus LHRH agonist and LHRH alone in premenopausal metastatic breast cancer patients who failed to tamoxifen treatment.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Metastatic Breast Cancer Estrogen Receptor Positive Tumor Breast Cancer Nos Premenopausal | Drug: Fulvestrant plus Goserelin Drug: Anastrozole plus Goserelin Drug: Goserelin | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 147 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Randomized Phase II Study OF Goserelin (G) Plus Fulvestrant (F) vs. G Plus Anastrozole (A)vs. G Alone for HR+, Tamoxifen Pretreated, Premenopausal Woman |
| Study Start Date : | December 2010 |
| Estimated Primary Completion Date : | June 2018 |
| Estimated Study Completion Date : | December 2019 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: Fulvestrant plus Goserelin |
Drug: Fulvestrant plus Goserelin
Fulvestrant s.c. plus Goserelin s.c.
Other Name: Anastrozole plus Goserelin Drug: Anastrozole plus Goserelin Anastrozole 1 mg p.o. plus Goserelin s.c.
Other Name: Fulvestrant plus Goserelin Drug: Goserelin Goserelin s.c.
Other Names:
|
| Experimental: Anastrozole plus Goserelin |
Drug: Fulvestrant plus Goserelin
Fulvestrant s.c. plus Goserelin s.c.
Other Name: Anastrozole plus Goserelin Drug: Anastrozole plus Goserelin Anastrozole 1 mg p.o. plus Goserelin s.c.
Other Name: Fulvestrant plus Goserelin Drug: Goserelin Goserelin s.c.
Other Names:
|
| Active Comparator: Goserelin alone |
Drug: Fulvestrant plus Goserelin
Fulvestrant s.c. plus Goserelin s.c.
Other Name: Anastrozole plus Goserelin Drug: Anastrozole plus Goserelin Anastrozole 1 mg p.o. plus Goserelin s.c.
Other Name: Fulvestrant plus Goserelin Drug: Goserelin Goserelin s.c.
Other Names:
|
- Time to Progression (TTP) [ Time Frame: from the date of therapy to the date of progression every 3 months ]To measure TTP, disease status will be measured every 3 cycles or clinically documented till progression
- overall response [ Time Frame: after 3 months from the first date of therapy ]Before start of 4th cycle of therapy, outcome measure will be perfomred to evaluate response
- overall survival [ Time Frame: from the first date of therapy till death ]from time to the first day of therapy to death
- Toxicity [ Time Frame: from the first date of therapy to death every cycle of therapy (monthly) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 55 Years (Child, Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
1) All patients must be female and premenopausal. Premenopausal is defined as either: ① last menstrual period within 3 months, or ② post-hysterectomy without bilateral oophorectomy and with FSH in the premenopausal range (≤ 30 mIU/mL), or, ③ if on tamoxifen within the past 3 months, a plasma estradiol in the premenopausal range (≥20 pg/mL), ④ if in case of chemotherapy induced amenorrhea, a plasma estradiol in the premenopausal range (≥20 pg/mL).
2) Patients must have either positive estrogen and/or progesterone receptor determination by IHC or competitive binding assay on metastatic disease, or if not performed on their metastatic disease a positive result on their primary breast cancer specimen.
3) No HER2 overexpressing breast cancer by IHC 3+ or FISH. 4) Patients who showed progressive disease on tamoxifen treatment as a palliative hormonal therapy or an adjuvant endocrine treatment 5) Patients who recurred after 5 years of tamoxifen use and could not be considered for resume to tamoxifen treatment.
6) No prior treatment with an aromatase inhibitor or inactivator or fulvestrant 7) No prior treatment with an LH/RH agonist/antagonist except the use for ovarian protection for 6 months during adjuvant chemotherapy.
8) No adjuvant chemotherapy within 1 year of study entry. 9) Patients must have an ECOG performance status of 0, 1, or 2. 10) Patients must have adequate bone marrow, hepatic, and renal function 11) Patients must not have received chemotherapy or hormonal therapy for at least 4 weeks prior to enrollment.
12) Patients may receive irradiation to any bony sites of disease for pain control or for prevention of fracture.
13) Patients may continue on bisphosphonates who already established on bisphosphonate therapy for at least 3 months.
14) Patients who are pregnant or lactating are ineligible. Must be using effective contraception or not be of childbearing potential.
15) Patients must not have had an active malignancy other than breast cancer, in situ carcinoma of the cervix, or non-melanomatous skin cancers in the past 5 years.
16) No active, unresolved infection. 17) All patients must give signed written informed consent
Exclusion Criteria:
- Patients who had received previous treatment for metastatic disease (including systemic cytostatic or hormonal treatment) other than tamoxifen.
- Lymphangitic pulmonary metastases
- Multiple or diffuse hepatic metastases
- Documented parenchymal or leptomeningeal brain metastasis
- HER-2 overexpressing breast cancer and concomitant trastuzumab treatment is not allowed
- Serious uncontrolled intercurrent infections
- Serious intercurrent medical or psychiatric illness, including active cardiac disease
- Pregnancy or breast feeding
- Second primary malignancy (except in situ carcinoma of the cervix or resected papillary thyroid carcinoma or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 5 years previously with no evidence of recurrence)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01266213
| Korea, Republic of | |
| Samsung Medical Center | |
| Seoul, Korea, Republic of, 135-710 | |
| Principal Investigator: | Young-Hyuck Im, M.D., Ph.D. | Samsung Medical Center |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Young-Hyuck Im, Professor, Samsung Medical Center |
| ClinicalTrials.gov Identifier: | NCT01266213 |
| Other Study ID Numbers: |
2010-04-001 |
| First Posted: | December 24, 2010 Key Record Dates |
| Last Update Posted: | May 1, 2017 |
| Last Verified: | April 2017 |
|
fulvestrant anastrozole goserelin |
tamoxifen premenopausal hormone receptor positive |
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Fulvestrant Anastrozole Goserelin Antineoplastic Agents, Hormonal Antineoplastic Agents |
Estrogen Receptor Antagonists Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Aromatase Inhibitors Steroid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |